Anti-cancer Properties of Myricetin Against HT-29 Colon Cancer Cells Through Regulation of RIPK1/RIPK3 Signaling Pathway

Hadis Alidadi¹,², Azin Samimi²,³, Masoud Ali Karami⁴, Layasadat Khorsandi¹,⁵ and Atefeh Ashtari¹,⁵, *

¹Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
²Department of Toxicology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
³Legal Medicine Research Center, Legal Medicine Organization, Ahvaz, Iran
⁴Nanotechnology Research Center, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
⁵Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Email: dr_atefeh_ashtari@yahoo.com

Received 2022 July 15; Revised 2022 July 28; Accepted 2022 July 29.

Abstract

Background: Myricetin (MCN), a dietary flavonoid, is present in walnuts, fruits, vegetables, tea, and berries and has been suggested as an anti-inflammatory, antiplatelet, antimicrobial, antioxidant, and antiviral drug.

Objectives: This study aimed to investigate whether the necroptosis pathway involves the toxic impacts of myricetin (MCN) on the colon adenoma-carcinoma HT-29 cells.

Methods: For 48 hours, HT-29 cells were exposed to 50 μM MCN or three mM Nec-1 (Necrosatine-1, a necroptosis preventive). Apoptosis, cell viability, and expression of necroptosis-related genes, including MLKL (mixed lineage kinase domain-like protein), RIPK1 (receptor-interacting protein kinase-1), and RIPK3, were evaluated.

Results: MCN caused a noticeable decline in the survival of HT-29 cells. In contrast to the slight change in the apoptosis index in HT-29 cells, MCN considerably increased the necrosis index. MCN could enhance the expression of MLKL, RIPK1, and RIPK3 in the HT-29 cells. The co-treatment of MCN with Nec-1 resulted in a significant elevation in HT-29 cell survival. Nec-1 could decrease the necrosis index and expression of necroptosis-related proteins in the MCN-exposed HT-29 cells.

Conclusions: These findings demonstrated that MCN effectively induced cell death in HT-29 cells by activating the necroptosis pathway.

Keywords: Myricetin, Necroptosis, Colon Cancer, Cytotoxicity

1. Background

Colorectal cancer (CRC) is one of the most common types of cancer worldwide. CRC incidence is predominantly associated with smoking, unhealthy eating habits, obesity, and aging. As a result of metastasis and drug resistance, this cancer has a high mortality rate despite conventional chemotherapy. The discovery of new anti-cancer drugs and the underlying molecular mechanisms can therefore help to treat this cancer (1). Recent cancer research has focused on natural compounds that can kill cancer cells with negligible side effects (2).

Myricetin (MCN) is a dietary flavonoid found in walnuts, fruits, vegetables, tea, and berries (3, 4). Recent studies suggest that MCN has anti-inflammatory, antiplatelet, antimicrobial, antioxidant, and antiviral properties. In addition, MCN exhibits cytotoxic effects on various cancer cells, including prostate, breast, skin, and gastric cancers (5, 6).

Necroptosis is a type of cell death program with similar features to apoptosis and necrosis, which has a critical role in managing many kinds of cancers and other disorders. Necroptosis activates as a signaling pathway to kill cancer cells when they are resistant to apoptosis. Several anti-cancer agents activate critical regulators of necroptosis signaling, including receptor-interacting protein kinase-1 (RIPK1), receptor-interacting protein kinase-3 (RIPK3), and mixed lineage kinase domain-like protein (MLKL). The activated RIPK1 binds to RIP3 to phosphorylate RIP3 and produce the necrosome complex. The necosome complex that interacts with MLKL and oligomerizes can disrupt membrane permeabilization, resulting in cell death (7).
2. Objectives

The current research aimed to investigate the involvement of the necroptosis pathway in the anti-cancer impact of the MCN on colon cancer (HT-29) cells (HT-29).

3. Methods

3.1. Cell Culture

HT-29 cell line was from the Iranian National and Genetic Center. The cells had grown in complete media and were maintained in a moist temperature incubator with 5% CO₂ and 37°C. After dissolving MCN in Dimethyl sulfoxide (DMSO), DMEM had used to dilute and obtain the desired concentration. A control group was exposed to only media, and the experimental groups were treated with three mM Necrostatine-1 (Nec-1, a necroptosis inhibitor), 50 µM MCN, and Nec-1 + MCN for 48 hours, respectively. Based on the MTT assay, the incubation time and concentration of MCN were selected (Figure 1). Nec-1 was also dissolved in 1% DMSO.

3.2. Cell Viability Assay

MTT (dimethylthazolyl 5-diphenyl tetrazolium bromide) test is applied to measure cellular metabolic activity for determining cell survival. It is a colorimetric method based on the cleavage of the tetrazolium ring of MTT by mitochondrial succinate dehydrogenase in living cells. Cells were exposed to MCN (0, 25, 50, 100, and 200 µM) for 24, 48, and 72 hours. The cells were then incubated with MTT solution (0.5 mg/mL) for 3 hours, and the supernatants were replaced with DMSO (100 l). Finally, the absorbance was measured at 570 nm.

3.3. Annexin V/PI Apoptosis Assay

The cells were harvested in 6-well dishes (10⁶ cells/well) and exposed to MCN or Nec-1 for 48 hours. Then, an Annexin V (FITC)/PI (propidium iodide) kit (Invitrogen, USA) was used to determine the percentages of the dead or survival cells by flow cytometry. The FITC/PI cells were viable, while FITC+/PI⁻, FITC⁻/PI⁻, and FITC⁻/PI⁺ cells indicated early apoptosis, late apoptosis, and necrosis stages, respectively.

3.4. Real-Time PCR

An RNase kit was used to isolate the RNA of the cells (10⁷ cells), and a cDNA kit was used to convert the RNA to cDNA. Two µL of the prepared cDNA amplified in a 25 µL PCR reaction contained SYBR Green and primers (Appendix 1 in Supplementary File). The following 45-cycle program was used to amplify the PCR: 95°C for 10 seconds, 95°C for 15 seconds, 60°C for 20 seconds, and 60°C for 20 seconds. The 2⁻∆∆CT method was applied to analyze the data.

3.5. Western Blotting Analysis

After treatment, HT-29 cells were washed and added to radioimmunoprecipitation (RIPA) lysis buffer. A BCA assay kit was used to determine the protein concentration within the cells. Lysate protein separated on 10% SDS-PAGE and transferred onto a PVDF membrane. The HT-29 cells were incubated with diluted primary antibodies (anti-RIPK1: ab178420; anti-RIPK3: ab222320; anti-MLKL: ab184718; anti-beta-Actin: ab15777) for 3 hours. The cells were then treated with horseradish peroxidase (HRP)-conjugated secondary antibody (ab205719) for 90 min. Proteins were detected using an ECL detection kit. Image J software was used to quantify the band density.

3.6. Statistical Analysis

Data were analyzed in SPSS (version 21.0) by one-way analysis of variance, followed by posthoc pairwise comparison with LSD or Kruskal-Wallis for non-parametric data. The P-values less than 0.05 were statistically significant.

4. Result

4.1. Cell Viability

As illustrated in Figure 1, after 24 hours of incubation with various doses of MCN, no considerable decline in the viability of the HT-29 cells was observed. A significant decrease in the cell survival rate from 100% in control to 78.1%, 49.8%, and 42.8% in 25, 50, and 100 µM-treated cells were observed during 48 hours, respectively. No cell survival rate alterations occurred during 72 hours of incubation with 100 and 200 µM/mL MCN compared to the 48 hours. Cell viabilities at the concentration of 200 µM MCN during 48 and 72 hours were 23.7% and 25.8%, respectively, and hence were considered lethal concentrations (Figure 1). The half-maximal inhibitory concentration (IC50) results had used to determine the half-maximal concentration of MCN required to inhibit the growth of HT-29 cells (Figure 2) compared to the only MCN-treated cells (P < 0.05).
Figure 1. The viability percentage of HT-29 cells in different concentrations and incubation times. Each assay has been done six times (4 replicates per assay), and the mean ± standard deviations have been indicated. * P < 0.05, ** P < 0.01, # P < 0.05; *, # and $ symbols indicate comparison to the control, and MCN50 groups.

Figure 2. The viability percentage of HT-29 cells (mean ± SD). Each assay was done six times. * P < 0.05, ** P < 0.01, # P < 0.05, $ P < 0.05; *, # and $ indicate comparison to the control, Nec-1, and MCN groups, respectively.
4.2. Annexin V-FITC/PI Assay

An annexin V/PI staining was performed to determine whether the MCN induced apoptosis or necrosis in HT-29 cells. In the untreated group, 98.9% of the cells were viable, 0.48% were in apoptosis, and 0.61% were in the necrosis stage. In comparison to the control, the proportion of viable cells decreased from 98.9 to 96.39%, 53.15%, and 81.1% in the Nec-1, MCN, and Nec-1 + MCN-treated cells, respectively. MCN slightly enhanced the percentage of apoptosis and the percentage of necrosis in HT-29 cells (75.7-fold, P < 0.001). Nec-1 + MCN caused a significant elevation in apoptosis (13.5-fold, P < 0.001), and a significant reduction in the necrosis (4.6-fold, P < 0.01) of the HT-29 cells compared to the MCN group (Figure 3).

4.3. Real-Time PCR Assay

The expression of the RIPK1 gene was low in the Nec-1-exposed HT-29 cells. RIPK3 and MLKL expression in cells exposed to Nec-1 were unchanged compared to the control. MCN significantly enhanced the expression of MLKL, RIPK1, and RIPK3 compared to the control (P < 0.01). In the Nec-1 + MCN group, the mRNA expression of MLKL and RIPK3 genes was considerably lower than in the MCN-treated cells (Figure 4).

4.4. Western Blotting Analysis

In HT-29 cells treated with Nec-1, the RIPK1 protein was not expressed. The protein levels of MLKL and RIPK3 in the Nec-1-exposed HT-29 cells were not changed compared to the control. MCN caused a significant elevation in the protein level of RIPK1, RIPK3, and MLKL compared to the control (P < 0.001). In the Nec-1 + MCN group, the protein expression of RIPK3 and MLKL was obviously lower than in the MCN-treated cells (P < 0.01) (Figure 5).

5. Discussion

This study demonstrated the cytotoxic effects of MCN on HT-29 cells. In line with our results, MCN inhibited the proliferation and survival rate of human papillary thyroid cancer (SNU-790 cells), cervical cancer (HeLa cells), and bladder cancer (8-10). In Xu et al. study, MCN had a high anti-proliferative effect on prostate cancer cells (11). Anthracyclines and oxaliplatin stimulate the necroptosis pathway by inducing the expression of RIPK3 and MLKL proteins in the malignant cells (23).

The increasing expression of necroptotic-related proteins was accompanied by decreasing survival of the MCN-treated cells. These findings suggest that MCN can inhibit the growth of the HT-29 cells by activating the necroptosis signaling pathway. This study examined the effects of Nec-1 on the HT-29 cells to evaluate the role of necroptosis. Cells exposed to Nec-1 exhibited enhanced growth, as well as reduced expression of RIK1, RIPK3, and MLKL. The enhancing growth of the HT-29 cells by Nec-1 indicates that necroptosis plays a crucial role in the anti-cancer effects of MCN. The results of this study showed that Nec-1 induces considerable apoptosis in the presence of MCN. Nec-1 can activate the caspase cascade (24) and may enhance apoptosis in MCN-treated HT-29 cells. Nec-1 induced apoptosis in Shikonin-exposed Leukemia cells (25). Interestingly, the increased apoptosis was accompanied by an increased survival rate in Nec-1+MCN-exposed HT-29 cells. As shown in the results, Nec-1 could decrease oxidative stress in the MCN-exposed cells and hence may increase the growth of the HT-29 cells.

5.1. Conclusions

Overall, this study demonstrated that MCN inhibits colon cancer cell growth effectively. MCN causes high cytotoxicity in HT-29 cells due to the stimulation of necroptosis signaling.
**Figure 3.** Flow cytometry results of Annexin V/PI staining (mean ± SD, n = 3). Lower left quadrant: live cells, Lower right quadrant: early apoptosis, Upper right quadrant: late apoptosis, Upper left quadrant: necrotic cells. * P < 0.05, ** P < 0.01, *** P < 0.001, # P < 0.05, ## P < 0.01, ### P < 0.001, $ P < 0.01.
Figure 4. mRNA expression of the different groups (mean ± SD, n=5). *P < 0.05, **P < 0.01, ***P < 0.001, # P < 0.05, ## P < 0.01, $ P < 0.05, $$ P < 0.001.
Figure 5. Protein expression of HT-29 cells in different groups (mean ± SD, n = 3). Image J software was used to quantify the protein levels, and the cells normalized to β-actin band intensity. * P < 0.01, ** P < 0.001, # P < 0.01, ## P < 0.001, $ P < 0.01, $$ P < 0.001.

Supplementary Material

Supplementary material(s) is available here [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Footnotes

Authors’ Contribution: HA, AS, and MAK conceived and designed the study; LK and AS acquired and analyzed the data; LK supervised the research. LK and AA drafted and revised the manuscript.

Conflict of Interests: Layasadat Khorsandi is a member of the Editorial Board of this journal.

Ethical Approval: The present study was approved by the Ethics Committee of the Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (Ethics code: IR.AJUMS.REC.1396.1120).

Funding/Support: The present study was funded by Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (CMRC-9640).

References


